Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AIC 284

Drug Profile

AIC 284

Alternative Names: AIC284; BAY-504798; IL2-mutein - AiCuris; Interleukin-2-mutein - AiCuris

Latest Information Update: 10 Mar 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer
  • Developer AiCuris; Bayer
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Immunostimulants; Interleukin-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Autoimmune disorders

Highest Development Phases

  • Phase I Autoimmune disorders
  • Discontinued Cancer; HIV infections

Most Recent Events

  • 25 Jan 2016 AIC 284 is available for licensing as of 25 Jan 2016. http://www.aicuris.com/
  • 25 Jan 2016 Phase-I clinical trials in Autoimmune disorders in Germany (Parenteral) (AiCuris pipeline; January 2016)
  • 15 Nov 2004 Phase-I/II clinical trials in HIV infections treatment in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top